An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
A phase 3 trial of Apalutamide, Abiraterone acetate and Prednisone in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.
Overview
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT02257736 by Aragon Pharmaceuticals, Inc., with 982 participants enrolled, started 2014-11-26 and due to reach its primary completion in 2018-03-19. Interventions recorded: Apalutamide, Abiraterone acetate, Prednisone and Placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide, Prostate cancer and the tag pipeline.
- TrialA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.